Posted by Michael Wonder on 06 Dec 2022
Germany's use of reference pricing for biologics: lessons for the US
5 December 2022 - A redesign of consumer cost sharing in the US is important to accelerate the adoption of biosimilars and price reductions for biologics.
This article analyses therapeutic reference pricing for anti-inflammatory biosimilars in Germany and its implications for the United States.
The German experience demonstrates that a redesign of consumer cost sharing can achieve savings for payers without creating onerous financial barriers for patients.
